Valery Krasnoperov

Chief Tech/Sci/R&D Officer at HALO COLLECTIVE INC.

Consumer Services

Commercial Services

Process Industries

Profile

Valery Krasnoperov is currently the Chief Scientific Officer at Halo Collective, Inc. Prior to this, he worked as the Director of Research & Development at VasGene Therapeutics, Inc. He also worked as a Research Scientist at New York University and The University of Nottingham.

Valery Krasnoperov active positions

Companies	Position	Start
HALO COLLECTIVE INC.	Chief Tech/Sci/R&D Officer	-

All active positions of Valery Krasnoperov

Former positions of Valery Krasnoperov

Companies	Position	End
New York University	Corporate Officer/Principal	-
The University of Nottingham	Corporate Officer/Principal	-
VasGene Therapeutics, Inc. VasGene Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services VasGene Therapeutics, Inc. developed therapeutics based on vascular biology. Its products included target signal transduction pathways common to cancer cells and endothelial cells, resulting in anti-cancer agents with multiple modes of action and inhibition of tumor cell growth, anti-angiogenesis and prevention of tumor cell metastasis. The company was founded by Raymond A. Mirra Jr. and Parkash Gill in 1999 and was headquartered in Oak Park, CA.	Chief Tech/Sci/R&D Officer	-

See the detail of Valery Krasnoperov's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Valery Krasnoperov's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
HALO COLLECTIVE INC.	Process Industries

Private companies	1
VasGene Therapeutics, Inc. VasGene Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services VasGene Therapeutics, Inc. developed therapeutics based on vascular biology. Its products included target signal transduction pathways common to cancer cells and endothelial cells, resulting in anti-cancer agents with multiple modes of action and inhibition of tumor cell growth, anti-angiogenesis and prevention of tumor cell metastasis. The company was founded by Raymond A. Mirra Jr. and Parkash Gill in 1999 and was headquartered in Oak Park, CA.	Commercial Services